Skip to content
Bora Haber
Markets
  • US dollar50.44up 0.05%
  • Euro55.34down 0.18%
  • British pound66.55down 0.11%
  • BIST 10011,477down 3.08%
  • Gold (gram)6,043down 3.53%
  • Gold (ounce)US$3,726down 3.58%
  • BitcoinUS$62,702down 1.5%
BREAKING

TÜBİTAK backs personalized cell and gene therapy projects as applications open

An international call has opened for innovative cell and gene therapy projects under personalized medicine. Partners in Türkiye can apply to TÜBİTAK until 27 January 2027.

Arda Sinyal

· 3 min read

A woman with curly dark hair in a white lab coat holds a tablet and green pen, looking down in a blurred laboratory.
A researcher taking notes in a laboratory; representative stock image. Temsili görsel · Fotoğraf: Mikhail Nilov / Pexels

An international project call has opened for developing innovative cell and gene therapies for human health within personalized medicine. It aims to develop and validate approaches that could offer higher efficacy, improved safety and longer-lasting effects than current standard treatments. Partners in Türkiye will submit their applications to TÜBİTAK.

Scope of the call

Researchers can propose projects in all disease areas. Solutions for diseases that could not be treated before will also be considered, and approaches focused on the underlying biological and genetic causes of diseases will be supported in moving into clinical practice. Applications must use at least one of the following: somatic cell, gene, combined cell and gene therapies, or new biological products.

Work on using stem cells, organoids and immune system cells for treatment, and on adding, altering or suppressing genes, falls within the support. Therapies developed with cells that are genetically modified before being given to patients may also be covered. Research on extracellular vesicles used as carriers in mRNA, other nucleic acid-based methods and gene-based therapies will also be supported.

Projects will use suitable preclinical models such as human cell cultures, organoids, organ-on-chip systems or animal models, present solid preliminary data and set out a feasible roadmap to clinical use. Studies on predicting treatment response and possible side effects, dose optimization, new manufacturing and delivery methods, and safety and efficacy assessment can be included, provided they are clearly linked to personalized cell and gene therapies.

Who can apply?

Higher education institutions, training and research hospitals, research infrastructures and other public bodies from Türkiye, as well as capital companies based in Türkiye with a trade registry certificate, can apply. Consortia must include at least 3 independent partners from at least 3 different European Union member or Horizon Europe-associated countries, who are eligible for support from their own funding bodies and are requesting it.

Funding amounts and rates

Projects can last up to 36 months. The total contribution Turkish partners can request from TÜBİTAK for a project, excluding institutional share and project incentive bonus, cannot exceed 200 bin euros. The cap per coordinating organization will be 100 bin euros for higher education institutions, training and research hospitals, research infrastructures and other public bodies, and 200 bin euros for private organizations.

On the approved budget, public bodies and universities will receive 100 percent support, SMEs 75 percent and large private organizations 60 percent. Private organizations' personnel, travel, consultancy, purchased services, instruments, machinery, equipment, software, publication and consumables costs may be supported; consultancy and services bought from international project partners are excluded.

Timeline

Short international project proposals will be prepared in English by project coordinators and submitted to the call secretariat by 20 January 2027. Turkish partners must complete their first-stage national applications to TÜBİTAK by 27 January 2027. First-stage results are expected around 9 April 2027, and consortia invited to the second stage can submit full international proposals by 25 May 2027. Projects are planned to start in December 2027.

Bora Haber previously reported: TÜBİTAK's 2027 Budget Proposal Allocates Major Share to R&D and Innovation Programs and Minister Kacır: We can delegate authority to AI, but not responsibility.

Technology guides

Take a quiz, vote in a poll

Video news

Comments

Sign in to comment.

More on this topic

See all